Patents Assigned to GUANGZHOU HYBRIBIO BIOTECH LTD.
  • Patent number: 11564891
    Abstract: A product for preventing and treating external genitalia infection and/or flat warts is provided, wherein the product comprises a chloroquine nanosphere. The chloroquine nanosphere comprises a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative. A mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier during preparation ranges from 1:3 to 1:5. A loading rate of the chloroquine or the chloroquine derivative in the prepared chloroquine nanosphere ranges from 3.0% to 21.6%. The water-soluble nanosphere carrier is water-soluble chitosan; a deacetylation degree of the water-soluble chitosan ranges from 80% to 95%, and a viscosity-average molecular weight thereof ranges from 3000 to 5000 g/mol. The chloroquine derivative is selected from one or more of hydroxychloroquine, chloroquine phosphate or chloroquine sulfate.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: January 31, 2023
    Assignees: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGZHOU HYBRIBIO BIOTECH LTD.
    Inventors: Longxu Xie, Xiangling Li, Manli Yuan, Ting Wang, Jianyu Wang
  • Publication number: 20210401763
    Abstract: A product for preventing and treating external genitalia infection and/or flat warts is provided, wherein the product comprises a chloroquine nanosphere. The chloroquine nanosphere comprises a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative. A mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier during preparation ranges from 1:3 to 1:5. A loading rate of the chloroquine or the chloroquine derivative in the prepared chloroquine nanosphere ranges from 3.0% to 21.6%. The water-soluble nanosphere carrier is water-soluble chitosan; a deacetylation degree of the water-soluble chitosan ranges from 80% to 95%, and a viscosity-average molecular weight thereof ranges from 3000 to 5000 g/mol. The chloroquine derivative is selected from one or more of hydroxychloroquine, chloroquine phosphate or chloroquine sulfate.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Applicants: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGZHOU HYBRIBIO BIOTECH LTD.
    Inventors: Longxu XIE, Xiangling LI, Manli YUAN, Ting WANG, Jianyu WANG
  • Patent number: 11147773
    Abstract: A chloroquine gel and a preparation method and application thereof. A chloroquine nanosphere includes a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative, wherein a mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier is no more than 1:3.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: October 19, 2021
    Assignees: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGZHOU HYBRIBIO BIOTECH LTD.
    Inventors: Longxu Xie, Xiangling Li, Manli Yuan, Ting Wang, Jianyu Wang
  • Publication number: 20200397713
    Abstract: A chloroquine gel and a preparation method and application thereof. A chloroquine nanosphere includes a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative, wherein a mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier is no more than 1:3.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 24, 2020
    Applicants: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGZHOU HYBRIBIO BIOTECH LTD.
    Inventors: Longxu XIE, Xiangling LI, Manli YUAN, Ting WANG, Jianyu WANG